Record Quarter, Missed Consensus — PharmaResearch's Split-Personality Q1

PharmaResearch's Q1 2026 results, announced May 8, look flawless at first glance. Revenue of KRW 146.1 billion, operating profit of KRW 57.3 billion, net income of KRW 48.7 billion — all three are quarterly records. Year-over-year, revenue rose 25%, operating profit rose 28%, and net income rose 35%. Yet the stock failed to gain traction after the release. The reason is simple: the absolute figures were record highs, but they still fell short of the bar the market had already set — the consensus. And the gap was driven by the company's flagship business, the "Rejuran" skin booster medical device division. What filled that gap was the comparatively under-the-radar Rejuran Cosmetics line, and within it, duty-free and foreign shopper spending in particular.

What Happened — Finalized Q1 2026 Results

PharmaResearch's Q1 2026 results by business segment were as follows.

Segment	Revenue	Domestic	Export
Medical Devices (skin boosters, etc.)	KRW 79.5 billion	KRW 58.4 billion	KRW 21.1 billion
Cosmetics (Rejuran Cosmetics)	KRW 42.2 billion	KRW 15.3 billion	KRW 26.9 billion
Pharmaceuticals	KRW 21.4 billion	KRW 11.2 billion	KRW 10.2 billion
Company-wide total	KRW 146.1 billion

Operating profit came to KRW 57.3 billion (operating margin 39.2%), and net income was KRW 48.7 billion. Yet the analyst consensus had called for revenue of KRW 150.7 billion and operating profit of KRW 60.3 billion — meaning the actual results fell about 3% short on revenue and about 5% short on operating profit relative to that bar. "Record-high results" and "consensus miss" can both be true at once precisely because the market had been expecting even bigger growth.

Key Insight #1 — The Miss Originated at Rejuran's Home Base: Medical Devices

What ate into the consensus wasn't cosmetics or pharmaceuticals — it was the company's core cash cow, the medical device division. Domestic medical device revenue of KRW 58.4 billion fell short of even the low end of the market's expected range (KRW 58.8 billion–60.3 billion), and exports of KRW 21.1 billion clearly missed forecasts (KRW 23.8 billion–24.0 billion). Exports in particular fell 10.2% quarter-over-quarter.

Analysts point to two causes. One is seasonality: "Q1 is the off-season for foreign dermatology spending," with inbound tourists' dermatology-related spending falling by as much as KRW 110 billion compared to the previous quarter. This isn't a figure specific to PharmaResearch alone — it reflects foreign tourists' overall dermatology spending in Korea. The other is structural: intensifying competition in the skin-booster market and downward pressure on unit prices, both of which took hold from the second half of 2025. This pressure isn't new. It's the same factor behind the 23% single-day stock plunge that followed the Q4 2025 earnings release on February 5 (revenue KRW 142.8 billion, operating profit KRW 51.8 billion, missing consensus by -8% and -20% respectively). In other words, this quarter hit an all-time high in absolute terms, but the very weakness (pricing pressure) that triggered the Q4 shock hasn't been fully resolved.

Deep Dive on Rejuran Cosmetics — Duty-Free Highlights

Cosmetics filled the gap left by medical devices. Rejuran Cosmetics revenue came to KRW 42.2 billion, up 51% year-over-year — the highest growth rate of any division — and its share of company-wide revenue jumped from 23.9% to 29%. Both domestic (KRW 15.3 billion, +43.3%) and export (KRW 26.9 billion, +55.8%) sales grew by double digits or more.

Here, duty-free's role needs to be addressed. But first, a caveat: PharmaResearch discloses cosmetics revenue only by domestic/export split and does not break out the duty-free channel separately. So a confirmed "duty-free revenue of X billion won" figure cannot be verified from company disclosures alone. Still, industry sources believe most Rejuran Cosmetics revenue comes from two channels — drugstores (like Olive Young) and duty-free — with duty-free accounting for a fairly sizable share. Indeed, Rejuran Cosmetics is carried at domestic duty-free stores including Shilla Duty Free's Yongsan I'Park Mall location.

The company itself cited "a surge in foreign shopping amid the combined effect of exchange rates and the holiday calendar" as the driver behind this quarter's 43.3% domestic cosmetics growth. In other words, much of the growth in domestic cosmetics sales came not from Korean consumers, but from the wallets of foreign tourists visiting Korea — suggesting duty-free and foreigner-focused stores were the primary conduit for this growth. Overseas distribution expansion added to this. Rejuran Cosmetics soft-launched on Sephora's U.S. online store on March 1, 2026, followed by a phased rollout starting March 16 to roughly 380 Sephora physical stores across the U.S. In China, it's also listed on Taobao, the country's largest open marketplace. With simultaneous entry into domestic duty-free and overseas specialty retail, Rejuran Cosmetics is building a structure that generates revenue from both foreign visitors to Korea and local consumers overseas at the same time.

Key Insight #2 — The Same Foreign Tourists Moved in Opposite Directions Across Two Channels

The most interesting part of this quarter's results lies elsewhere. PharmaResearch's business connects to foreign tourists in two distinct ways — one is medical tourism demand for Rejuran treatments at dermatology clinics (tied to domestic medical device revenue), and the other is retail demand for Rejuran Cosmetics purchased at duty-free stores and counters (tied to domestic cosmetics revenue). This quarter, the two channels moved in opposite directions. Foreign dermatology spending plunged KRW 110 billion quarter-over-quarter, while foreign shopping for Rejuran Cosmetics surged, lifting domestic cosmetics revenue by 43.3%.

In other words, the same foreign tourists got fewer treatments and did more shopping in the same quarter. This connects to the broader shift RIT has previously tracked in its K-beauty field series — a shift in weight from group-tour, treatment-centered spending toward individual-tourism, retail-centered spending. But this case shows something more: within a single company, the same customer can send opposite signals depending on which channel you're standing in. Looking only at the medical device division, you'd worry that "foreign demand has slumped"; looking at cosmetics, the company was celebrating that "foreign shopping surged."

Business Impact — European Expansion and the Q2 Outlook

On the medical device export side, Europe has emerged as a new variable. Shipments to Europe through French distributor VIVACY were partially reflected in Q1, bringing first-half European exports to about KRW 6.0 billion. If a similar volume of shipments continues in the second half, full-year European exports could reach roughly KRW 12.0 billion — potentially exceeding the original full-year guidance.

Q2 2026 results had not yet been announced as of this writing. The market expects revenue of KRW 162.4 billion and operating profit of KRW 65.0 billion, an improvement over Q1 — though these are forecasts, not confirmed figures. Some analysts note that given the high base from the same period last year (Q2 2025 results), the growth rate itself could slow compared to Q1. Ultimately, the key question is whether the medical device division shows a combined domestic and export recovery as it enters its seasonal peak (Q2), or whether cosmetics continues to fill the gap.

Practical Implications

• Investor/analyst leads: This case shows that "record-high results" and "consensus miss" can be true at the same time. Beyond the headline growth rate, it's essential to check the miss relative to market expectations, and which specific division drove the miss.
• Duty-free/retail MD leads: For companies like PharmaResearch that don't disclose duty-free separately, cross-referencing domestic revenue growth rates against management commentary on "foreign shopping" can offer an indirect read on the duty-free channel's real contribution.
• Business portfolio leads: Even when targeting the same customer base, demand can move in opposite directions across channels like medical tourism (treatment) versus retail (shopping). To avoid mistaking weakness in one channel for a broader customer exodus, track channel-level metrics separately.
• Brand expansion leads: A dual-distribution strategy — simultaneous entry into domestic duty-free and overseas specialty retail like Sephora — targeting both inbound tourists and local consumers can offset the seasonal swings of any single channel, as this case illustrates.

Conclusion

PharmaResearch's Q1 was a quarter where the absolute numbers and the market's expectations diverged. The company's core skin-booster medical device business still carries the same issue that triggered last quarter's stock crash — a sharp drop in inbound dermatology demand combined with pricing competition pressure. What filled that gap was Rejuran Cosmetics, up 51%, with much of that growth coming from duty-free and foreign shopping. The fact that the same foreign tourists closed their wallets at the dermatology clinic while opening them at the store is a contrast that will remain a useful lens for reading the next quarter's results too.